Relmada Therapeutics reduced its quarterly net loss to $10.1 million from $21.7 million a year ago, supported by lower R&D and G&A spending. The company ended the quarter with $13.9 million in cash and short-term investments, not including a $94 million raise in early November.

In Q2 2025, Relmada posted a net loss of $9.9M, or $0.30 per share, compared to a $17.8M loss a year earlier, driven by a 74% drop in R&D expenses and reduced G&A costs. The company ended the quarter with $20.6M in cash, equivalents, and short-term investments, and 33.2M shares outstanding.

Relmada Therapeutics, Inc. reported a net loss of $17.56 million for the three months ended March 31, 2025, with total operating expenses of $18.22 million. The company's cash and cash equivalents decreased significantly, raising substantial doubt about its ability to continue as a going concern.

Relmada Therapeutics reported a net loss of $18.6 million for Q4 2024, an improvement from $25.1 million in Q4 2023. The company ended the year with a cash balance of $44.8 million and is focused on advancing its NDV-01 and sepranolone programs.

Relmada Therapeutics announced progress in its Phase 3 program for REL-1017 and plans for a Phase 1 trial for REL-P11, while also reporting financial results for the fourth quarter and full year ended December 31, 2023.

Relmada Therapeutics announced its third quarter financial results and provided a corporate update, highlighting the progress of its Phase 3 clinical development plan for REL-1017 and upcoming milestones.

Relmada Therapeutics reported their Q2 2023 earnings, highlighting the ongoing Phase 3 clinical development plan for REL-1017 and anticipating data readouts from both Phase 3 trials in 2024. The company also stated that they are sufficiently funded to execute their plans.

Relmada Therapeutics reported its first quarter 2023 financial results, focusing on the development program of REL-1017 for major depressive disorder. Enrollment is progressing for Study 302, with trial completion anticipated in the first half of 2024, and site selection has been finalized for the new planned Study 304.

Relmada Therapeutics reported their Q4 and full-year 2022 financial results, focusing on the analysis of Reliance I (Study 301) data and plans for further development of REL-1017 as an adjunctive treatment for major depressive disorder (MDD). They intend to implement changes to Reliance II (Study 302) and initiate a new trial, Study 304, with sufficient funding to execute these plans.

Relmada Therapeutics announced Q3 2022 financial results, with a focus on the ongoing evaluation of REL-1017 for major depressive disorder (MDD). Top-line results from the RELIANCE III trial were recently announced, and the company anticipates further results from RELIANCE I before the year's end. Enrollment continues for RELIANCE II, with top-line results expected in 2023.

Relmada Therapeutics reported its first quarter 2022 financial results, highlighting the progress of its REL-1017 clinical data readouts for the Reliance Phase 3 program.

Relmada Therapeutics reported its Q4 and full year 2021 financial results, highlighting the completion of two human abuse potential studies confirming no meaningful abuse potential of REL-1017 and anticipating multiple key data readouts throughout the remainder of the year.

Relmada Therapeutics reported their Q4 and full-year 2020 financial results, highlighting the initiation of their Phase 3 program for REL-1017 and anticipating multiple data readouts over the next several quarters. The company also reported a strong balance sheet to drive development efforts.